Cost-effectiveness of the use of vector control and mass drug administration, separately or in combination, against lymphatic filariasis.
Identifieur interne : 009482 ( Main/Exploration ); précédent : 009481; suivant : 009483Cost-effectiveness of the use of vector control and mass drug administration, separately or in combination, against lymphatic filariasis.
Auteurs : K. Krishnamoorthy [Inde] ; R. Rajendran ; I P Sunish ; R. ReubenSource :
- Annals of tropical medicine and parasitology [ 0003-4983 ] ; 2002.
Descripteurs français
- KwdFr :
- Analyse coût-bénéfice, Animaux, Association de médicaments, Culex (parasitologie), Diéthylcarbamazine (usage thérapeutique), Diéthylcarbamazine (économie), Filaricides (usage thérapeutique), Filaricides (économie), Filariose lymphatique (), Filariose lymphatique (transmission), Filariose lymphatique (économie), Humains, Inde, Ivermectine (usage thérapeutique), Ivermectine (économie), Lutte contre les moustiques (), Lutte contre les moustiques (économie), Maladies endémiques (), Maladies endémiques (économie), Santé en zone rurale, Vecteurs de maladie, Wuchereria bancrofti.
- MESH :
- parasitologie : Culex.
- usage thérapeutique : Diéthylcarbamazine, Filaricides, Filariose lymphatique, Ivermectine.
- économie : Diéthylcarbamazine, Filaricides, Filariose lymphatique, Ivermectine, Lutte contre les moustiques, Maladies endémiques.
- Analyse coût-bénéfice, Animaux, Association de médicaments, Filariose lymphatique, Humains, Inde, Lutte contre les moustiques, Maladies endémiques, Santé en zone rurale, Vecteurs de maladie, Wuchereria bancrofti.
- Wicri :
- geographic : Inde.
English descriptors
- KwdEn :
- Animals, Cost-Benefit Analysis, Culex (parasitology), Diethylcarbamazine (economics), Diethylcarbamazine (therapeutic use), Disease Vectors, Drug Therapy, Combination, Elephantiasis, Filarial (economics), Elephantiasis, Filarial (prevention & control), Elephantiasis, Filarial (transmission), Endemic Diseases (economics), Endemic Diseases (prevention & control), Filaricides (economics), Filaricides (therapeutic use), Humans, India, Ivermectin (economics), Ivermectin (therapeutic use), Mosquito Control (economics), Mosquito Control (methods), Rural Health, Wuchereria bancrofti.
- MESH :
- chemical , economics : Diethylcarbamazine, Filaricides, Ivermectin.
- chemical , therapeutic use : Ivermectin.
- geographic : India.
- economics : Elephantiasis, Filarial, Endemic Diseases, Mosquito Control.
- methods : Mosquito Control.
- parasitology : Culex.
- prevention & control : Elephantiasis, Filarial, Endemic Diseases.
- chemical , therapeutic use : Diethylcarbamazine, Filaricides.
- transmission : Elephantiasis, Filarial.
- Animals, Cost-Benefit Analysis, Disease Vectors, Drug Therapy, Combination, Humans, Rural Health, Wuchereria bancrofti.
Abstract
The costs and effects of two intervention strategies for the control of bancroftian filariasis-annual mass drug administrations (MDA) with a combination of diethylcarbamazine and ivermectin, with or without integrated vector control (VC)-were estimated in rural villages in South India. The aim was to compare the cost-effectiveness of MDA alone with that of MDA plus VC. Control of the local vector, Culex quinquefasciatus, was based on the application of polystyrene beads to cesspits, the treatment of drains with larvicidal Bacillus sphaericus and the stocking of wells with larvivorous fish. An itemized cost menu was used to cost MDA and MDA + VC, retrospectively. The annual transmission potential was used to assess the direct outcome of the disease-control methods, whereas the prevalence and intensity of microfilaraemia were used as indicators of the impact of each method. The per-capita costs were 1.49 U.S. dollars for two rounds of MDA, 1.70 U.S. dollars for 2 years of VC and, therefore, 3.19 U.S. dollars for 2 years of MDA + VC. Integration of VC with MDA did not appear to be cost-effective: it cost an estimated 1.80 U.S. dollars to stop an infective mosquito biting a villager using MDA alone but 3.32 U.S. dollars to achieve the same result using MDA + VC. Similarly, the cost to reduce the prevalence of microfilaraemia in a three-village group by 1% was only 96.62 U.S. dollars for MDA alone but 201.16 U.S. dollars when vector control was integrated. The implications of these results for the control and elimination of filariasis in Indian village communities, and the options for sharing and minimizing costs, are discussed.
DOI: 10.1179/000349802125002428
PubMed: 12625921
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 004338
- to stream PubMed, to step Curation: 004338
- to stream PubMed, to step Checkpoint: 004338
- to stream Ncbi, to step Merge: 000C67
- to stream Ncbi, to step Curation: 000C67
- to stream Ncbi, to step Checkpoint: 000C67
- to stream Main, to step Merge: 009851
- to stream Main, to step Curation: 009482
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cost-effectiveness of the use of vector control and mass drug administration, separately or in combination, against lymphatic filariasis.</title><author><name sortKey="Krishnamoorthy, K" sort="Krishnamoorthy, K" uniqKey="Krishnamoorthy K" first="K" last="Krishnamoorthy">K. Krishnamoorthy</name><affiliation wicri:level="1"><nlm:affiliation>Vector Control Research Centre (ICMR), Medical Complex, Indira Nagar, Pondicherry - 605 006, India. kkrish_3@yahoo.com</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Vector Control Research Centre (ICMR), Medical Complex, Indira Nagar, Pondicherry - 605 006</wicri:regionArea><wicri:noRegion>Pondicherry - 605 006</wicri:noRegion></affiliation></author><author><name sortKey="Rajendran, R" sort="Rajendran, R" uniqKey="Rajendran R" first="R" last="Rajendran">R. Rajendran</name></author><author><name sortKey="Sunish, I P" sort="Sunish, I P" uniqKey="Sunish I" first="I P" last="Sunish">I P Sunish</name></author><author><name sortKey="Reuben, R" sort="Reuben, R" uniqKey="Reuben R" first="R" last="Reuben">R. Reuben</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2002">2002</date><idno type="RBID">pubmed:12625921</idno><idno type="pmid">12625921</idno><idno type="doi">10.1179/000349802125002428</idno><idno type="wicri:Area/PubMed/Corpus">004338</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">004338</idno><idno type="wicri:Area/PubMed/Curation">004338</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">004338</idno><idno type="wicri:Area/PubMed/Checkpoint">004338</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">004338</idno><idno type="wicri:Area/Ncbi/Merge">000C67</idno><idno type="wicri:Area/Ncbi/Curation">000C67</idno><idno type="wicri:Area/Ncbi/Checkpoint">000C67</idno><idno type="wicri:doubleKey">0003-4983:2002:Krishnamoorthy K:cost:effectiveness:of</idno><idno type="wicri:Area/Main/Merge">009851</idno><idno type="wicri:Area/Main/Curation">009482</idno><idno type="wicri:Area/Main/Exploration">009482</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Cost-effectiveness of the use of vector control and mass drug administration, separately or in combination, against lymphatic filariasis.</title><author><name sortKey="Krishnamoorthy, K" sort="Krishnamoorthy, K" uniqKey="Krishnamoorthy K" first="K" last="Krishnamoorthy">K. Krishnamoorthy</name><affiliation wicri:level="1"><nlm:affiliation>Vector Control Research Centre (ICMR), Medical Complex, Indira Nagar, Pondicherry - 605 006, India. kkrish_3@yahoo.com</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Vector Control Research Centre (ICMR), Medical Complex, Indira Nagar, Pondicherry - 605 006</wicri:regionArea><wicri:noRegion>Pondicherry - 605 006</wicri:noRegion></affiliation></author><author><name sortKey="Rajendran, R" sort="Rajendran, R" uniqKey="Rajendran R" first="R" last="Rajendran">R. Rajendran</name></author><author><name sortKey="Sunish, I P" sort="Sunish, I P" uniqKey="Sunish I" first="I P" last="Sunish">I P Sunish</name></author><author><name sortKey="Reuben, R" sort="Reuben, R" uniqKey="Reuben R" first="R" last="Reuben">R. Reuben</name></author></analytic><series><title level="j">Annals of tropical medicine and parasitology</title><idno type="ISSN">0003-4983</idno><imprint><date when="2002" type="published">2002</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Cost-Benefit Analysis</term><term>Culex (parasitology)</term><term>Diethylcarbamazine (economics)</term><term>Diethylcarbamazine (therapeutic use)</term><term>Disease Vectors</term><term>Drug Therapy, Combination</term><term>Elephantiasis, Filarial (economics)</term><term>Elephantiasis, Filarial (prevention & control)</term><term>Elephantiasis, Filarial (transmission)</term><term>Endemic Diseases (economics)</term><term>Endemic Diseases (prevention & control)</term><term>Filaricides (economics)</term><term>Filaricides (therapeutic use)</term><term>Humans</term><term>India</term><term>Ivermectin (economics)</term><term>Ivermectin (therapeutic use)</term><term>Mosquito Control (economics)</term><term>Mosquito Control (methods)</term><term>Rural Health</term><term>Wuchereria bancrofti</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Analyse coût-bénéfice</term><term>Animaux</term><term>Association de médicaments</term><term>Culex (parasitologie)</term><term>Diéthylcarbamazine (usage thérapeutique)</term><term>Diéthylcarbamazine (économie)</term><term>Filaricides (usage thérapeutique)</term><term>Filaricides (économie)</term><term>Filariose lymphatique ()</term><term>Filariose lymphatique (transmission)</term><term>Filariose lymphatique (économie)</term><term>Humains</term><term>Inde</term><term>Ivermectine (usage thérapeutique)</term><term>Ivermectine (économie)</term><term>Lutte contre les moustiques ()</term><term>Lutte contre les moustiques (économie)</term><term>Maladies endémiques ()</term><term>Maladies endémiques (économie)</term><term>Santé en zone rurale</term><term>Vecteurs de maladie</term><term>Wuchereria bancrofti</term></keywords><keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Diethylcarbamazine</term><term>Filaricides</term><term>Ivermectin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Ivermectin</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>India</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Elephantiasis, Filarial</term><term>Endemic Diseases</term><term>Mosquito Control</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Mosquito Control</term></keywords><keywords scheme="MESH" qualifier="parasitologie" xml:lang="fr"><term>Culex</term></keywords><keywords scheme="MESH" qualifier="parasitology" xml:lang="en"><term>Culex</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Elephantiasis, Filarial</term><term>Endemic Diseases</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Diethylcarbamazine</term><term>Filaricides</term></keywords><keywords scheme="MESH" qualifier="transmission" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Diéthylcarbamazine</term><term>Filaricides</term><term>Filariose lymphatique</term><term>Ivermectine</term></keywords><keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Diéthylcarbamazine</term><term>Filaricides</term><term>Filariose lymphatique</term><term>Ivermectine</term><term>Lutte contre les moustiques</term><term>Maladies endémiques</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cost-Benefit Analysis</term><term>Disease Vectors</term><term>Drug Therapy, Combination</term><term>Humans</term><term>Rural Health</term><term>Wuchereria bancrofti</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Analyse coût-bénéfice</term><term>Animaux</term><term>Association de médicaments</term><term>Filariose lymphatique</term><term>Humains</term><term>Inde</term><term>Lutte contre les moustiques</term><term>Maladies endémiques</term><term>Santé en zone rurale</term><term>Vecteurs de maladie</term><term>Wuchereria bancrofti</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Inde</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The costs and effects of two intervention strategies for the control of bancroftian filariasis-annual mass drug administrations (MDA) with a combination of diethylcarbamazine and ivermectin, with or without integrated vector control (VC)-were estimated in rural villages in South India. The aim was to compare the cost-effectiveness of MDA alone with that of MDA plus VC. Control of the local vector, Culex quinquefasciatus, was based on the application of polystyrene beads to cesspits, the treatment of drains with larvicidal Bacillus sphaericus and the stocking of wells with larvivorous fish. An itemized cost menu was used to cost MDA and MDA + VC, retrospectively. The annual transmission potential was used to assess the direct outcome of the disease-control methods, whereas the prevalence and intensity of microfilaraemia were used as indicators of the impact of each method. The per-capita costs were 1.49 U.S. dollars for two rounds of MDA, 1.70 U.S. dollars for 2 years of VC and, therefore, 3.19 U.S. dollars for 2 years of MDA + VC. Integration of VC with MDA did not appear to be cost-effective: it cost an estimated 1.80 U.S. dollars to stop an infective mosquito biting a villager using MDA alone but 3.32 U.S. dollars to achieve the same result using MDA + VC. Similarly, the cost to reduce the prevalence of microfilaraemia in a three-village group by 1% was only 96.62 U.S. dollars for MDA alone but 201.16 U.S. dollars when vector control was integrated. The implications of these results for the control and elimination of filariasis in Indian village communities, and the options for sharing and minimizing costs, are discussed.</div></front></TEI><affiliations><list><country><li>Inde</li></country></list><tree><noCountry><name sortKey="Rajendran, R" sort="Rajendran, R" uniqKey="Rajendran R" first="R" last="Rajendran">R. Rajendran</name><name sortKey="Reuben, R" sort="Reuben, R" uniqKey="Reuben R" first="R" last="Reuben">R. Reuben</name><name sortKey="Sunish, I P" sort="Sunish, I P" uniqKey="Sunish I" first="I P" last="Sunish">I P Sunish</name></noCountry><country name="Inde"><noRegion><name sortKey="Krishnamoorthy, K" sort="Krishnamoorthy, K" uniqKey="Krishnamoorthy K" first="K" last="Krishnamoorthy">K. Krishnamoorthy</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 009482 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 009482 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:12625921
|texte= Cost-effectiveness of the use of vector control and mass drug administration, separately or in combination, against lymphatic filariasis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:12625921" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |